SCHEMBL15069494

SCHEMBL15069494

CCC(=O)C1CCC2(CC1)OCCO2

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.44
LMNA P02545 1/20 0.44
ALDH1A1 P00352 7/20 0.40
TSHR P16473 3/20 0.40
KMT2A Q03164 4/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 1/20 0.37
CYP2C19 P33261 3/20 0.35
MEN1 O00255 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
HPGD P15428 1/20 0.34
TP53 P04637 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15125166 0.80 LMNA (0.36) MAPK1LMNAALDH1A1TSHRKMT2A
SCHEMBL2203295 0.79 LMNA (0.41) MAPK1LMNAALDH1A1TSHRKMT2A
SCHEMBL594661 0.79 ALDH1A1 (0.38) MAPK1LMNAALDH1A1TSHRKMT2A
SCHEMBL21987643 0.79 ALDH1A1 (0.40) MAPK1LMNAALDH1A1TSHRKMT2A
SCHEMBL583466 0.79 POLB (0.43) MAPK1LMNAALDH1A1TSHRKMT2A
SCHEMBL5618 0.77 CYP3A4 (0.49) MAPK1LMNAALDH1A1SMN1; SMN2POLB
SCHEMBL17558795 0.77 LMNA (0.35) MAPK1LMNAALDH1A1TSHRKMT2A
SCHEMBL12615396 0.77 CTSS (0.41) MAPK1LMNAALDH1A1TSHRKMT2A
SCHEMBL256670 0.76
SCHEMBL3631699 0.75 APLNR (0.34) LMNAALDH1A1TSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023142754-A1 EZH1/2 INHIBITOR, PREPARATION THEREOF, AND USE THEREOF IN ANTI-TUMOR THERAPY 江苏天士力帝益药业有限公司 2023-08-03 WO disclosed
US-9309211-B2 Arylalkene derivatives and use thereof as selective estrogen receptor modulators CENTAURUS BIOPHARMA CO., LTD. (CN) 2016-04-12 US disclosed
US-9309211-B2 Arylalkene derivatives and use thereof as selective estrogen receptor modulators CENTAURUS BIOPHARMA CO., LTD. (CN) 2016-04-12 US disclosed
US-9309211-B2 Arylalkene derivatives and use thereof as selective estrogen receptor modulators CENTAURUS BIOPHARMA CO., LTD. (CN) 2016-04-12 US disclosed
EP-2797889-A1 NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS Centaurus Biopharma Co., Ltd. (CN) 2014-11-05 EP disclosed
WO-2013097773-A1 NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS CENTAURUS BIOPHARMA CO., LTD. (CN) 2013-07-04 WO disclosed
WO-2013097773-A1 NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS CENTAURUS BIOPHARMA CO., LTD. (CN) 2013-07-04 WO disclosed